Month: August 2020

OpGen Group Company Ares Genetics Demonstrates Feasibility of CLIA-compliant Next Generation Sequencing Workflow for Identification of Bacterial Pathogens and Antibiotic Resistance Markers

Written by Customer Service on August 11, 2020. Posted in Public Companies.

Accurate identification of antibiotic resistance markers based on the ARESdb QIAGEN CLC Module leveraging Ares Genetics’ proprietary antibiotic resistance databasePathogens correctly identified with 100% sensitivity and specificity, antibiotic resistance markers with >95% sensitivity and >99% specificity, respectivelyStudy paves the way for routine clinical diagnostic application of next-generation sequencing (NGS) in timely as well as accurate infectious disease testing and drug susceptibility predictionVIENNA, Austria, and GAITHERSBURG, Md., Aug. 11, 2020 (GLOBE NEWSWIRE) — Ares Genetics GmbH (Vienna, Austria; “Ares Genetics”), a subsidiary of OpGen, Inc. (Nasdaq: OPGN, “OpGen”), announced today the publication of a peer-reviewed study that demonstrates the feasibility of a highly accurate and reproducible sample-to-insight workflow...

AnPac Bio Opens US Philadelphia Lab Operations

Written by Customer Service on August 11, 2020. Posted in Public Companies.

SAN JOSE, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, announced today that the Company has commenced operations of its new Philadelphia lab, with the completion of its facility renovation and first phase equipment installation in July 2020. A Roche Cobas e411 machine, a diagnostic analyzer, which has received the FDA’s Emergency Use Authorization for performing COVID-19 anti-body tests, is among the Laboratory’s first phase equipment.“AnPac Bio plans to perform both cancer screening research on its CDA technology and offer for commercial purposes COVID-19 antibody tests using the Roche Cobas e411 machine once these tests have been respectively qualified and approved as per...

aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Proceeds to Phase 1 Trial of ATYR1923 in Japan

Written by Customer Service on August 11, 2020. Posted in Public Companies.

SAN DIEGO, Aug. 11, 2020 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that its partner Kyorin Pharmaceutical Co., Ltd., or Kyorin, a wholly owned subsidiary of Kyorin Holdings, Inc., has initiated clinical development in Japan for aTyr’s lead therapeutic candidate ATYR1923 (known as KRP-R120 in Japan) following the Pharmaceutical and Medical Devices Agency (PMDA) review of its Clinical Trial Notification (CTN) submission. The CTN permits the start of clinical development activities in Japan for ATYR1923. The Phase 1 study, which will be conducted by Kyorin, will evaluate the safety, pharmacokinetics and immunogenicity of ATYR1923 in healthy male volunteers in Japan.“We are pleased...

Kitov Pharma Provides Corporate Update and Reports First Half 2020 Financial Results

Written by Customer Service on August 11, 2020. Posted in Public Companies.

TEL AVIV, Israel, Aug. 11, 2020 (GLOBE NEWSWIRE) — Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today provided a corporate update and announced financial results for the six months ended June 30, 2020.“The first half of 2020 represented a transformative period for Kitov, with multiple commercial, clinical and corporate milestones achieved,” said Isaac Israel, Chief Executive Officer. “Importantly, we have successfully completed our evolution to an oncology-focused biotechnology company with the acquisition of CM24, an inhibitor of CEACAM1, and our strong cash balance at the end of the first half of the year of over $60 million positions us well to continue building a pipeline of attractive oncology assets. Moreover,...

WisdomTree Prices Offering of $25.0 Million of 4.25% Convertible Senior Notes

Written by Customer Service on August 11, 2020. Posted in Public Companies.

NEW YORK, Aug. 11, 2020 (GLOBE NEWSWIRE) — WisdomTree Investments, Inc. (NASDAQ: WETF) (“WisdomTree”) today announced the pricing of an offering of $25.0 million aggregate principal amount of its convertible senior notes due 2023 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), at an issue price of 101% of par value plus accrued interest from June 16, 2020. The sale of the notes to the initial purchaser is expected to settle on August 13, 2020, subject to customary closing conditions, and is expected to result in approximately $24.2 million in net proceeds to WisdomTree after deducting the initial purchaser’s discount and estimated offering expenses payable by WisdomTree. WisdomTree intends to use approximately...

DSS Announces Shareholder Approval for its Acquisition of Impact Biomedical

Written by Customer Service on August 11, 2020. Posted in Public Companies.

ROCHESTER, N.Y., Aug. 11, 2020 (GLOBE NEWSWIRE) — Document Security Systems, Inc. (“DSS” or the “Company”) (NYSE American: DSS), a multinational company operating businesses focusing on brand protection technology, blockchain security, direct marketing, healthcare, real estate, and securitized digital assets, is pleased to announce its shareholders voted to approve the Company’s acquisition of Impact BioMedical as outlined in the share exchange agreement (“Transaction”) announced on April 27, 2020, signed by DSS, DSS BioHealth Security, Inc. (a wholly-owned direct subsidiary of DSS), Impact BioMedical Inc. (“Impact BioMedical”) and Global BioMedical Pte. Ltd. (“Global BioMedical”). Global BioMedical, which owns all of the stock of Impact BioMedical, is a 100% owned subsidiary of Singapore eDevelopment Limited (“SeD”) (SGX: 40V).Frank...

Applied Optoelectronics Announces Record Laser Production

Written by Customer Service on August 11, 2020. Posted in Public Companies.

SUGAR LAND, Texas, Aug. 11, 2020 (GLOBE NEWSWIRE) — Applied Optoelectronics, Inc. (NASDAQ: AAOI), a leading provider of fiber-optic access network products for the internet datacenter, cable broadband, telecom and fiber-to-the-home (FTTH) markets, today announced that production of laser diodes in July, 2020 reached an all-time record of over 1.1 million units, nearly 65% higher than pre-COVID levels.“AOI has been investing in capacity by adding additional production equipment, improving our manufacturing processes to increase yield and enhance quality, and adding staff,” said Dr. Thompson Lin, Applied Optoelectronics Inc. Founder and CEO. “The result of this hard work and investment is that we’ve reached a significant milestone in terms of laser production capacity. The vast majority of our current laser production is 25G lasers...

Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2020 Financial Results

Written by Customer Service on August 11, 2020. Posted in Public Companies.

– Conference call scheduled for 8:00 a.m. ET today –CAMBRIDGE, Mass., Aug. 11, 2020 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today provided a business update and reported financial results for the second quarter of 2020.“The team at Fulcrum not only delivered key progress across our pipeline this quarter, but also expanded our work into additional areas of critical unmet need,” said Robert J. Gould, Ph.D., president and chief executive officer. “We are encouraged by the data from the ReDUX4 interim analysis announced earlier today, suggesting that muscles with the highest DUX4-driven gene expression in pre-treatment biopsies show greater reduction in DUX4-driven gene expression following...

Larimar Therapeutics Reports Second Quarter 2020 Operating and Financial Results

Written by Customer Service on August 11, 2020. Posted in Earnings Releases And Operating Results.

Merger between Chondrial Therapeutics and Zafgen completed and company began operating as Larimar TherapeuticsPhase 1 clinical trial of CTI-1601 for treatment of Friedreich’s ataxia restarts after delay due to COVID-19 related restrictions$80 million private placement financing completed with biotechnology-focused institutional investorsPositive opinion on Orphan Drug Designation for CTI-1601 from the European Medicines Agency Committee for Orphan Medicinal Products New Board Chair, Chief Medical Officer and Chief Financial Officer appointedBALA CYNWYD, Pa., Aug. 11, 2020 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its second quarter 2020 operating and financial results.“The second quarter was a transformative...

Axovant Announces Corporate Updates and Financial Results for First Fiscal Quarter Ended June 30, 2020

Written by Customer Service on August 11, 2020. Posted in Earnings Releases And Operating Results.

Data readouts for AXO-Lenti-PD and AXO-AAV-GM1 remain on-track for Q4 2020Completed 3-year manufacturing and supply agreement with Oxford BioMedica for AXO-Lenti-PDCompany had $55.5 million of cash and cash equivalents as of June 30, 2020NEW YORK and BASEL, Switzerland, Aug. 11, 2020 (GLOBE NEWSWIRE) — Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage gene therapy company developing innovative gene therapies for neurodegenerative diseases, today provided financial results for its first fiscal quarter ended June 30, 2020.“During our first fiscal quarter, we continued to make significant progress across our three clinical-stage gene therapy development programs in Parkinson’s disease, GM1 gangliosidosis and Tay-Sachs/Sandhoff diseases and remain on-track for key data readouts later this year,” said Pavan Cheruvu, M.D.,...

Month: August 2020

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals